# OnCo record tqb2102 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tqb2102/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tqb2102" ;
  schema:name "TQB2102"@en ;
  schema:description "TQB2102 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, HER2-positive breast cancer and biliary tract cancer, aimed at HER2."@en ;
  schema:url <https://onco.cc/drugs/tqb2102/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=TQB2102> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "ADC" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> ;
  onco:trials <https://onco.cc/trials/nct07003074/>, <https://onco.cc/trials/nct06561607/>, <https://onco.cc/trials/nct07008976/>, <https://onco.cc/trials/nct07043725/>, <https://onco.cc/trials/nct06496490/>, <https://onco.cc/trials/nct07512583/>, <https://onco.cc/trials/nct06431490/>, <https://onco.cc/trials/nct06452706/>, <https://onco.cc/trials/nct06198751/> .